Pharmacophore modeling and virtual screening studies of checkpoint kinase 1 inhibitors

18Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

In this study, chemical feature-based 3-dimensional (3D) pharmacophore models of Checkpoint kinase 1 (Chk1) inhibitors were developed based on the known inhibitors of Chk1. The best pharmacophore model Hypo1 was characterized by the best correlation coefficient (0.9577), and the lowest root mean square deviation (0.8871). Hypo1 consists of one hydrogen-bond acceptor, one hydrogen-bond donor, and two hydrophobic features, as well as one excluded volume. This pharmacophore model was further validated by both test set and cross validation methods. A comparison analysis of Hypo1 with chemical features in the active site of Chk1 indicates that the pharmacophore model Hypo1 can correctly reflect the interactions between Chk1 and its ligands. Then Hypo1 was used to screen chemical databases, including Specs and Chinese Nature Product Database (CNPD) for potential lead compounds. The hit compounds were subsequently subjected to filtering by Lipinski's rule of five and docking study to refine the retrieved hits. Finally some of the most potent (estimated) compounds were selected from the final refined hits and suggested for further experimental investigation. © 2009 Pharmaceutical Society of Japan.

Cite

CITATION STYLE

APA

Chen, J. J., Liu, T. L., Yang, L. J., Li, L. L., Wei, Y. Q., & Yang, S. Y. (2009). Pharmacophore modeling and virtual screening studies of checkpoint kinase 1 inhibitors. Chemical and Pharmaceutical Bulletin, 57(7), 704–709. https://doi.org/10.1248/cpb.57.704

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free